TWI609959B - Parabacteroides merdae for reducing weight gaining, body fat accumulation and triglyceride in liver, composition comprising the same, and use thereof - Google Patents
Parabacteroides merdae for reducing weight gaining, body fat accumulation and triglyceride in liver, composition comprising the same, and use thereof Download PDFInfo
- Publication number
- TWI609959B TWI609959B TW105143338A TW105143338A TWI609959B TW I609959 B TWI609959 B TW I609959B TW 105143338 A TW105143338 A TW 105143338A TW 105143338 A TW105143338 A TW 105143338A TW I609959 B TWI609959 B TW I609959B
- Authority
- TW
- Taiwan
- Prior art keywords
- composition
- liver
- accumulation
- body fat
- triglyceride
- Prior art date
Links
Landscapes
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
本揭露係關於一種新穎之屎副擬桿菌及包含其之組成物及其用途，其可達到減少體重獲得、體脂肪堆積或肝臟中三酸甘油酯累積之目的。 The present disclosure relates to a novel Bacteroides bacillus and compositions comprising the same and uses thereof for the purpose of reducing body weight gain, body fat accumulation or accumulation of triglycerides in the liver.
Description
本揭露係關於一種新穎的屎副擬桿菌及包含其之組成物及其用途，尤指一種可減少體重獲得、體脂肪堆積或肝臟中三酸甘油酯累積之屎副擬桿菌及包含其之組成物及其用途。 The present disclosure relates to a novel Bacteroides bacillus and a composition comprising the same, and a use thereof, and more particularly to a Bacteroides bacillus which can reduce body weight gain, body fat accumulation or accumulation of triglycerides in the liver and the composition thereof. And its use.
根據統計，肥胖與心血管疾病、第二型糖尿病、高血脂症、脂肪肝、精神健康息息相關。因此，肥胖為影響身體健康的因素之一。其中，肥胖所觀察到的現象不外乎是體重增加及/或體脂肪堆積。當長時間熱量吸收多於熱量消耗，將導致體重增加；且對於成年人而言，體重增加的一部分原因是由於體內的脂肪組織增多及體脂肪增加。 According to statistics, obesity is closely related to cardiovascular disease, type 2 diabetes, hyperlipidemia, fatty liver, and mental health. Therefore, obesity is one of the factors that affect your health. Among them, the phenomenon observed in obesity is nothing more than weight gain and / or body fat accumulation. When long-term heat absorption is more than calorie consumption, it will lead to weight gain; and for adults, part of the reason for weight gain is due to increased adipose tissue and increased body fat in the body.
除了肥胖以外，肝臟中三酸甘油酯的累積，也為影響身體健康的因素之一。當血液中三酸甘油酯量過高時，也會導致高血脂症；而高血脂症除會導致心臟疾病之外，也與腦中風、高血壓、糖尿病、腎病等慢性疾病息息相關。 In addition to obesity, the accumulation of triglycerides in the liver is also one of the factors affecting health. When the amount of triglyceride in the blood is too high, it can also lead to hyperlipidemia; in addition to causing heart disease, hyperlipidemia is also associated with chronic diseases such as stroke, hypertension, diabetes, and kidney disease.
現代人對於健康議題日漸重視，目前各廠商無不積極開發可減少體重獲得、體脂肪堆積或肝臟中三酸甘油酯累積之藥品、保健食品等。有鑑於 此，若能提供一種新穎方法，能達到減少體重獲得、體脂肪堆積或肝臟中三酸甘油酯累積，則可避免前述相關疾病的發生，而達到維持健康、延長壽命的目的。 Modern people are paying more and more attention to health issues. At present, all manufacturers are actively developing drugs and health foods that can reduce body weight gain, body fat accumulation or accumulation of triglycerides in the liver. In view of Therefore, if a novel method can be provided to achieve weight loss, body fat accumulation or triglyceride accumulation in the liver, the aforementioned diseases can be avoided, and the purpose of maintaining health and prolonging life can be achieved.
本揭露之主要目的係在提供一種新穎的屎副擬桿菌( Parabacteroides merdae )，其可用於減少體重獲得、體脂肪堆積或肝臟中三酸甘油酯累積。 The main object of the present disclosure is to provide a novel Parabacteroides merdae which can be used to reduce body weight gain, body fat accumulation or accumulation of triglycerides in the liver.
本揭露所提供的屎副擬桿菌，其係寄存於中華民國食品工業發展研究所，寄存編號為BCRC910758。 The pseudobacteria provided by the present disclosure is deposited in the Republic of China Food Industry Development Institute, and the registration number is BCRC910758.
此外，前述屎副擬桿菌更可與其他載體合併使用，製作成一組成物。因此，本揭露更提供一種減少體重獲得、體脂肪堆積或肝臟中三酸甘油酯累積之組成物，包括：前述之屎副擬桿菌、以及一載體。 In addition, the aforementioned Bacteroides sputum can be used in combination with other carriers to prepare a composition. Accordingly, the present disclosure further provides a composition for reducing body weight gain, body fat accumulation, or triglyceride accumulation in the liver, including: the aforementioned Bacteroides bacillus, and a vector.
再者，本揭露更提供前述屎副擬桿菌之用途，其係用以製備減少體重獲得、體脂肪堆積或肝臟中三酸甘油酯累積之組成物。 Furthermore, the present disclosure further provides the use of the aforementioned Bacteroides bacillus for preparing a composition for reducing body weight gain, body fat accumulation or accumulation of triglyceride in the liver.
此外，本揭露所提供屎副擬桿菌及包含其之組成物，可投予一所需主體，而於所需主體中達到前述減少體重獲得、體脂肪堆積或肝臟中三酸甘油酯累積等目的。在此，所需主體之例子包括哺乳動物，如：牛、豬、人類等。 In addition, the present disclosure provides a Bacteroides and a composition comprising the same, which can be administered to a desired subject, and achieve the aforementioned reduction in body weight gain, body fat accumulation or accumulation of triglyceride in the liver in the desired body. . Here, examples of the desired subject include mammals such as cows, pigs, humans, and the like.
本揭露所提供屎副擬桿菌及包含其之組成物，可透過口服、腸道外、局部、直腸、含服、或透過植入型藥盒投藥；且較佳係以口服的方式投藥。 The present disclosure provides Bacteroides bacillus and compositions comprising the same, which can be administered orally, parenterally, topically, rectally, orally, or via an implantable kit; and preferably administered orally.
於本揭露中，載體的種類並無特殊限制，只要能與組成物中之屎副擬桿菌相匹配，且較佳為能穩定屎副擬桿菌活性且而對被治療主體不造成不良影響。例如，載體可為乳糖、葡萄糖、蔗糖、山梨糖醇、甘露糖、澱粉、***膠、磷酸鈣、藻酸鹽、明膠、矽酸鈣、膠體二氧化矽、硬脂酸鎂、月桂基 硫酸鈉、微晶纖維素、聚乙烯吡咯烷酮、纖維素、水、糖漿、甲基纖維素、羥基苯甲酸甲酯、羥基苯甲酸丙酯、滑石、硬脂酸鎂和礦物油中的至少一種。 In the present disclosure, the kind of the carrier is not particularly limited as long as it can match the Bacteroides in the composition, and preferably stabilizes the activity of Bacteroides and does not adversely affect the subject to be treated. For example, the carrier can be lactose, glucose, sucrose, sorbitol, mannose, starch, gum arabic, calcium phosphate, alginate, gelatin, calcium citrate, colloidal cerium oxide, magnesium stearate, lauryl At least one of sodium sulfate, microcrystalline cellulose, polyvinylpyrrolidone, cellulose, water, syrup, methylcellulose, methyl hydroxybenzoate, propyl hydroxybenzoate, talc, magnesium stearate, and mineral oil.
於本揭露之組成物中，屎副擬桿菌之含量並無特殊限制，只要能達成前述減少體重獲得、體脂肪堆積或肝臟中累積之目的之有效劑量即可。其中，屎副擬桿菌於組成物中的含量可介於106cfu至1010cfu之間。例如，屎副擬桿菌之管餵含量為108cfu。 In the composition of the present disclosure, the content of Bacteroides bacillus is not particularly limited as long as the above-mentioned effective dose for the purpose of reducing body weight gain, body fat accumulation or accumulation in the liver can be achieved. Wherein, the content of Bacteroides sinensis in the composition may be between 10 6 cfu and 10 10 cfu. For example, the tube feeding amount of Bacteroides bacillus is 10 8 cfu.
本揭露之組成物之應用領域並無特殊限制，可為一醫藥組成物、一保健用品、一食品或一飼料。 The application field of the composition of the present disclosure is not particularly limited and may be a pharmaceutical composition, a health care product, a food or a feed.
此外，本揭露之組成物之形式也無特殊限制，可為一錠劑、一膠囊、一溶液製品、一乳化溶、一粉末、或一懸浮液。前述的劑型可以本技術領域已知的方法並搭配適當的載劑製備。舉例而言，在錠劑的情形下，常使用的載體包括乳糖及玉米澱粉。此外，若需要，也可選擇性的於前述劑型中加入甘味劑、香味劑或著色劑。 Further, the form of the composition of the present disclosure is not particularly limited and may be a tablet, a capsule, a solution, an emulsion, a powder, or a suspension. The foregoing dosage forms can be prepared by methods known in the art and with suitable carriers. For example, in the case of lozenges, carriers which are commonly used include lactose and corn starch. Further, if desired, a sweetener, a flavoring agent or a coloring agent may optionally be added to the aforementioned dosage form.
圖1為餵食六週後小鼠的體重變化百分比圖。 Figure 1 is a graph showing the percentage change in body weight of mice after six weeks of feeding.
圖2為餵食六週後小鼠的脂肪組織照片。 Figure 2 is a photograph of adipose tissue of mice after six weeks of feeding.
圖3為餵食六週後小鼠的脂肪組織重量。 Figure 3 shows the adipose tissue weight of mice after six weeks of feeding.
圖4為餵食六週後小鼠的肝臟切片油紅組織染色圖片。 Figure 4 is a picture of oil red staining of liver sections of mice after six weeks of feeding.
圖5為餵食六週後小鼠的肝臟中三酸甘油酯含量結果圖。 Figure 5 is a graph showing the results of triglyceride content in the liver of mice after six weeks of feeding.
以下係藉由特定的具體實施例說明本揭露之實施方式，熟習此技藝之人士可由本說明書所揭示之內容輕易地了解本揭露之其他優點與功效。本揭露亦可藉由其他不同的具體實施例加以施行或應用，本說明書中的各項細節亦可針對不同觀點與應用，在不悖離本創作之精神下進行各種修飾與變更。 The embodiments of the present disclosure are described by way of specific examples, and those skilled in the art can readily appreciate the other advantages and advantages of the disclosure. The disclosure may also be implemented or applied by other different embodiments. The details of the present specification may also be applied to various aspects and applications, and various modifications and changes may be made without departing from the spirit of the present invention.
於本揭露之下述實施例中，所謂之「NLAC-1菌」即為屎副擬桿菌( Parabacteroides merdae )，其係寄存於中華民國食品工業發展研究所，寄存編號為BCRC910758。 In the following examples of the present disclosure, the so-called "NLAC-1 bacteria" is Parabacteroides merdae , which is deposited in the Republic of China Food Industry Development Institute, and the registration number is BCRC910758.
組成物的配製 Composition preparation
NLAC-1菌是培養在血瓊脂平板(blood agar plate)，放置35℃厭氧環境培養3天後，將培養基上的菌落刮取下來並使用肉汁培養液(broth)稀釋至108cfu/0.5ml，待管餵動物使用。 NLAC-1 was cultured on a blood agar plate and placed in an anaerobic environment at 35 ° C for 3 days. The colonies on the medium were scraped off and diluted to 10 8 cfu/0.5 using broth. Ml, to be used for feeding animals.
測試例 Test case
3-4週大SPF C57BL/6JNarl公鼠分別給予Lab5010和60%高脂飼料後6週。兩種飼料餵食之動物分別以體重由小排到大分別以S型分組方式進行分組後，動物除了餵食Lab5010和60%高脂飼料外，另外分別在每週一、三和五餵食培養液或NLAC-1菌(108cfu/0.5ml/隻)，連續6週後，動物進行犧牲後量測體重、脂肪重量並進行檢體採樣。 3-4 weeks old SPF C57BL/6JNarl male rats were given Lab5010 and 60% high fat diet for 6 weeks. Animals fed by two kinds of feeds were divided into small groups and large groups by S-type grouping. The animals were fed with Lamb-type and three-to-five feeds, respectively, in addition to Lab5010 and 60% high-fat diets. NLAC-1 bacteria (10 8 cfu / 0.5 ml / only), after 6 weeks, the animals were sacrificed, body weight, fat weight were measured and sampled.
於本測試例中，係使用C57BL/6JNARL公鼠進行測試，每組包括10-13隻小鼠。將小鼠分為為五組，分別為(1)餵食Lab5010飼料和培養基的Lab5010+M組、(2)餵食Lab5010飼料和NLAC-1菌的Lab5010+B組、(3)餵食60%的高脂飼料和培養基的HFD+M組、(4)餵食60%的高脂飼料以及NLAC-1菌的HFD+B組、及(5)餵食60%的高脂飼料已殺死之NLAC-1菌的HFD+KB組。每週一、三、五進行餵食，餵食量為108cfu/0.5ml/隻；連續餵食六週後犧牲小鼠。 In this test, C57BL/6JNARL male mice were used for testing, each group consisting of 10-13 mice. The mice were divided into five groups, (1) Lab5010+M group fed Lab5010 feed and medium, (2) Lab5010+B group fed Lab5010 feed and NLAC-1 bacteria, and (3) 60% high fed. HFD+M group for fat diet and medium, (4) 60% high fat diet and NLAC-1 strain HFD+B group, and (5) 60% high fat diet killed NLAC-1 bacteria HFD+KB group. Feeding was performed every Monday, Wednesday and Friday with a feeding volume of 10 8 cfu/0.5 ml/head; the mice were sacrificed after six weeks of continuous feeding.
圖1為餵食六週後小鼠所發生的體重變化百分比圖。圖中不同字母a、b、c表示經由one-way ANOVA方式統計出不同組別之間有顯著差異(p<0.05)。由圖1結果顯示，HFD+B組所增加的體重比例顯著性少於HFD+M組；此結果表示，餵食高脂肪飼料同時餵食NLAC-1菌可有效降低體重之增加。 Figure 1 is a graph showing the percentage change in body weight that occurs in mice after six weeks of feeding. The different letters a, b, and c in the figure indicate that there is a significant difference (p < 0.05) between the different groups via the one-way ANOVA method. The results in Figure 1 show that the weight gain of the HFD+B group is significantly less than that of the HFD+M group; this result indicates that feeding high-fat diet while feeding NLAC-1 bacteria can effectively reduce the weight gain.
於犧牲小鼠後，以肉眼觀察各組取出之白色脂肪組織，包含副睪兩側之脂肪、腎臟週圍脂肪和皮下脂肪。所得的脂肪組織包含副睪兩側之脂肪和腎臟週圍脂肪照片係如圖2所示；而脂肪組織之量化結果係如圖3所示，每組數值之標準差已被標示，且圖中不同字母a、b、c表示經由one-way ANOVA方式統計出不同組別之間有顯著差異(p<0.05)。 After sacrificing the mice, the white adipose tissue extracted from each group was visually observed, including the fat on both sides of the parasitoid, the fat around the kidney, and the subcutaneous fat. The obtained adipose tissue contains the fat on both sides of the parasitoid and the photo of the fat around the kidney as shown in Fig. 2; and the quantitative results of the adipose tissue are shown in Fig. 3, and the standard deviation of each group of values has been marked, and the figure is different. The letters a, b, and c indicate that there was a significant difference (p < 0.05) between the different groups via the one-way ANOVA method.
如圖2及圖3結果所示，HFD+B組所具有之脂肪組織少於HFD+M組；此結果表示，餵食高脂肪飼料同時餵食NLAC-1菌，可有效降低脂肪組織堆積。 As shown in the results of Fig. 2 and Fig. 3, the HFD+B group had less adipose tissue than the HFD+M group; this result indicated that feeding high-fat diet and feeding NLAC-1 bacteria can effectively reduce the accumulation of adipose tissue.
此外，於犧牲小鼠後，更以油紅組織染色(Oil red stain)處理小鼠肝臟組織，染色結果係顯示於圖4。再者，更量測小鼠肝臟中三酸甘油酯含量，結果係如圖5所示；其中，每組數值之標準差已被標示，且圖中不同字母a、b表示經由one-way ANOVA方式統計出不同組別之間有顯著差異(p<0.05)。 In addition, after sacrificing the mice, the liver tissue of the mice was treated with oil red stain, and the staining results are shown in Fig. 4. Furthermore, the triglyceride content in the liver of the mouse was measured, and the results are shown in Fig. 5; wherein the standard deviation of each group of values has been indicated, and the different letters a and b in the figure indicate via one-way ANOVA. Methods showed significant differences between the different groups (p < 0.05).
由圖4及圖5結果顯示，HFD+B組肝臟中三酸甘油酯量少於HFD+M組；此結果表示，餵食高脂肪飼料同時餵食NLAC-1菌可降低肝臟中油滴(三酸甘油脂)之增加。 The results of Fig. 4 and Fig. 5 show that the amount of triglyceride in the liver of HFD+B group is less than that of HFD+M group; this result indicates that feeding high-fat diet while feeding NLAC-1 bacteria can reduce oil droplets in the liver (tristearate) The increase in fat).
由前述結果顯示，HFD+B組之小鼠體重增加、脂肪組織堆積、及肝臟中三酸甘油酯的量均少於HFD+M組；代表著當餵食本揭露所提供的NLAC-1菌，可有效達到減少體重獲得、體脂肪堆積或肝臟中三酸甘油酯累積。特別是，可有效減少高脂肪飲食主體之體重獲得、體脂肪堆積或肝臟中三酸甘油酯累積。 From the foregoing results, the weight gain, adipose tissue accumulation, and the amount of triglyceride in the liver of the mice in the HFD+B group were all less than those in the HFD+M group; it represents the NLAC-1 bacteria provided when feeding the present disclosure. It can effectively achieve weight loss gain, body fat accumulation or accumulation of triglycerides in the liver. In particular, it can effectively reduce body weight gain, body fat accumulation or accumulation of triglycerides in the liver of a high-fat diet.
上述實施例僅係為了方便說明而舉例而已，本揭露所主張之權利範圍自應以申請專利範圍所述為準，而非僅限於上述實施例。 The above-mentioned embodiments are merely examples for convenience of description, and the scope of the claims is intended to be limited to the above embodiments.
TW中華民國財團法人食品工業發展研究所2016/12/21寄存編號BCRC910758。 TW Republic of China Foundation Food Industry Development Institute 2016/12/21 Registration number BCRC910758.
Claims (7)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| TW105143338A TWI609959B (en) | 2016-12-27 | 2016-12-27 | Parabacteroides merdae for reducing weight gaining, body fat accumulation and triglyceride in liver, composition comprising the same, and use thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| TW105143338A TWI609959B (en) | 2016-12-27 | 2016-12-27 | Parabacteroides merdae for reducing weight gaining, body fat accumulation and triglyceride in liver, composition comprising the same, and use thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| TWI609959B true TWI609959B (en) | 2018-01-01 |
| TW201823444A TW201823444A (en) | 2018-07-01 |
Family
ID=61728268
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| TW105143338A TWI609959B (en) | 2016-12-27 | 2016-12-27 | Parabacteroides merdae for reducing weight gaining, body fat accumulation and triglyceride in liver, composition comprising the same, and use thereof |
Country Status (1)
| Country | Link |
|---|---|
| TW (1) | TWI609959B (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN111714522A (en) * | 2019-03-04 | 2020-09-29 | 中国科学院微生物研究所 | Bacteroides and application thereof |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104726596A (en) * | 2014-03-28 | 2015-06-24 | 首尔大学校产学协力团 | Early diagnosis of obesity-related diseases using changes in the gut microbial community structure and function |
-
2016
- 2016-12-27 TW TW105143338A patent/TWI609959B/en not_active IP Right Cessation
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104726596A (en) * | 2014-03-28 | 2015-06-24 | 首尔大学校产学协力团 | Early diagnosis of obesity-related diseases using changes in the gut microbial community structure and function |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN111714522A (en) * | 2019-03-04 | 2020-09-29 | 中国科学院微生物研究所 | Bacteroides and application thereof |
| CN111714522B (en) * | 2019-03-04 | 2022-07-15 | 中国科学院微生物研究所 | Bacteroides and application thereof |
Also Published As
| Publication number | Publication date |
|---|---|
| TW201823444A (en) | 2018-07-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP7528153B2 (en) | Methods and compositions using Bifidobacterium longum for treating or preventing depressive symptoms | |
| JP5259905B2 (en) | Medium chain fatty acids applicable as antibacterial agents | |
| BRPI0417826B1 (en) | composition comprising a canine probiotic pseudolongum bifidobacterial strain | |
| BRPI0611492A2 (en) | feline probiotic bifidobacterium | |
| BRPI0611493A2 (en) | feline probiotic lactobacilli | |
| Mehri et al. | Mentha piperita (peppermint) in growing Japanese quails diet: Performance, carcass attributes, morphology and microbial populations of intestine | |
| Abbasi et al. | Postbiotics: science, technology and applications | |
| JP6596135B2 (en) | Composition for improving intestinal environment, inhibiting weight gain by ingesting a high-fat diet, or inhibiting H. pylori | |
| JP2024500474A (en) | A novel Bifidobacterium animalis lactis HEM20-01 strain, and a composition for treating depression comprising the strain or a culture thereof | |
| WO2019045037A1 (en) | Composition for promoting production of hyaluronic acid | |
| JPWO2010005047A1 (en) | Intestinal environment improver | |
| Mudroňová et al. | Effect of fungal gamma-linolenic acid and beta-carotene containing prefermented feed on immunity and gut of broiler chicken | |
| TWI719691B (en) | Use of lactobacillus reuteri gkr1 for preparing composition of reducing uric acid | |
| TWI609959B (en) | Parabacteroides merdae for reducing weight gaining, body fat accumulation and triglyceride in liver, composition comprising the same, and use thereof | |
| WO2023237067A1 (en) | Use of akkermansia muciniphila in preparation of pharmaceutical composition or health care product composition for improving metabolic syndrome | |
| Birmani et al. | Probiotic supplementation in poultry production as an alternative to antibiotic feed additive | |
| JP7123341B2 (en) | PGC-1α biosynthesis promoter and slow-twitch fast-twitch inhibitor | |
| WO2015115865A1 (en) | Antituberculous composition containing artesunate or gamma linolenic acid for treating and preventing tuberculosis | |
| JPWO2009014127A1 (en) | Composition for preventing or treating diseases associated with autoantibody production | |
| JP2014005225A (en) | Agent for suppressing appetite improvement and body weight gain | |
| US9480722B2 (en) | Method of alleviating or treating periodontal disease | |
| Chen et al. | Lactic acid bacteria and foodborne pathogens | |
| JP7377978B2 (en) | pet food composition | |
| Al-Faragi et al. | Effect of local probiotic on common carp Cyprinus carpio growth performance and survival rate | |
| KR102606636B1 (en) | Bacillus velezensis having the effect of preventing or improving for sarcopenia and uses thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MM4A | Annulment or lapse of patent due to non-payment of fees |